REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDuke Capital Regulatory News (DUKE)

Share Price Information for Duke Capital (DUKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 33.00
Bid: 32.50
Ask: 33.50
Change: 0.00 (0.00%)
Spread: 1.00 (3.077%)
Open: 33.00
High: 33.00
Low: 33.00
Prev. Close: 33.00
DUKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading and Operational Update

28 Mar 2024 07:00

RNS Number : 6028I
Duke Capital Limited
28 March 2024
 

28 March 2024

Duke Capital Limited

 

("Duke Capital", "Duke" or the "Company")

 

Trading and Operational Update

 

Duke Capital Limited (AIM: DUKE), a leading provider of hybrid capital solutions for SME business owners in Europe and North America, is pleased to provide the following trading update for its third quarter of the financial year ending 31 December 2023 ("Q3 FY24"), and to provide guidance on trading for its fourth quarter ending 31 March 2024 ("Q4 FY24").

 

Q3 FY24 Trading Update

 

· Recurring revenue for Q3 FY24 reached a record of £6.3 million, an increase of 12% over Q3 FY23. Total cash revenue was also £6.3 million.

 

· Q3 FY24 represents over three continuous years of increasing quarterly recurring cash revenue, with total growth of 350% from the £1.8 million in the quarter ending September 2020 to £6.3 million for the last quarter ending December 2023.

 

Q4 FY24 Trading Guidance

 

· Duke forecasts total cash revenue of £10.2 million in Q4 FY24, a record quarter marking the first time Duke has generated more than £10 million in a single quarter. This represents a material 30% increase over the Company's previous record of £7.8 million which was achieved in Q1 FY24.

 

· During the quarter, Duke delivered two material and profitable buyouts, that have returned over £19 million which the Company will use for near-term deployments in new and existing partners.

 

· Duke expects to achieve recurring cash revenue of £5.8 million in Q4 FY24, a small decrease versus the previous quarter. While the recent buyouts have resulted in increased total cash revenue, until this capital is redeployed, there is a temporary impact of reduced recurring cash revenue. 

 

Overview of quarterly revenue growth:

 

 

Recurring Cash Revenue*

Total Cash Revenue**

Q3 FY23

£5.6 million

£5.6 million

Q4 FY23

£5.7 million

£5.8 million

Q1 FY24

£6.0 million

£7.8 million

Q2 FY24

£6.2 million

£6.2 million

Q3 FY24

£6.3 million

£6.3 million

 

* Recurring cash revenue excludes exit premium receipts and cash gains from equity sales

** Total cash revenue is monthly cash distributions from Duke's partners plus cash gains received from the sales of equity assets and exit premiums

 

 

Operational Update

 

· In February, Duke completed a £2.9 million secondary share purchase from existing shareholders in United Glass Group, increasing its equity stake from 30% to 74%, in line with Duke Capital's vision to deepen its engagement with its high performing partners.

· In March, Duke delivered two highly profitable exits from Fabrikat and Fairmed Healthcare, which has significantly bolstered Duke's liquidity which currently stands at approximately £44 million.

· The Company has a strong pipeline of both new and follow-on opportunities for capital partners to deploy additional liquidity.

· During the quarter, Duke also completed its change of name and renewed messaging. The review has focused on ensuring that Duke's unique offering is communicated to business owners and stakeholders in a way which provides greater clarity and improves comparison when evaluating a broad array of financing options.

 

Neil Johnson, CEO of Duke Capital, said:

 

"We are delighted to show a record quarter of total cash revenue following the successful exits of two of our investments. Fabrikat particularly highlighted the value of Duke's capital, having financed an MBO by three executives in 2021, facilitating an exit three years later at a 36% IRR. We look forward to redeploying the capital from these exits into our pipeline of immediate and longer-term opportunities, driving a return in the short-term to delivering record quarterly recurring cash revenues.

 

Following the completion of our name change and corporate re-branding, Duke Capital is looking forward to FY25 with renewed optimism. With a strengthened liquidity position and strong pipeline, we are well-equipped to navigate the challenges and opportunities that lie ahead, while remaining cautious of the economic backdrop."

 

 

***ENDS***

 

For further information, please visit https://dukecapital.com/ or contact:

 

Duke Capital Limited

Neil Johnson / Charles Cannon Brookes / Hugo Evans

 

+44 (0) 1481 231 816

Cavendish Capital Markets Limited (Nominated Adviser and Joint Broker)

Stephen Keys / Callum Davidson / Michael Johnson 

+44 (0) 207 220 0500

 

Canaccord Genuity Limited

(Joint Broker)

 

Adam James / Harry Rees

+44 (0) 207 523 8000

SEC Newgate (Financial Communications)

Elisabeth Cowell / Alice Cho / Matthew Elliott

+ +44 (0) 20 3757 6882 dukecapital@secnewgate.co.uk

 

 

About Duke Capital

 

Duke is a leading provider of hybrid capital solutions for SME business owners in Europe and North America, combining the best features of both equity and debt.

 

Since 2017, Duke has provided unique long-term financing which eliminates re-financing risk and necessity for a short-term exit by providing a unique 'corporate mortgage' while also aligning its returns to grow with the success of the business.

 

Duke is focused on generating attractive risk-adjusted returns for shareholders and has a track record of achieving this across market cycles. It's three investment pillars are capital preservation, attractive dividend yield, and to provide upside upon exits.

 

Duke is listed on the AIM market under the ticker DUKE and is headquartered in Guernsey.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTQKOBPKBKBANB
Date   Source Headline
22nd Jun 20177:00 amRNSFinal Results
9th Jun 20177:00 amRNSRoyalty Partner Operational Update
6th Apr 20177:00 amRNSInaugural royalty financing agreement
28th Mar 20177:00 amRNSHolding(s) in Company
24th Mar 20172:55 pmRNSHolding(s) in Company
23rd Mar 20175:00 pmRNSRe-Admission and First Day of Dealings
22nd Mar 20173:45 pmRNSSch 1 Update - Duke Royalty Limited
20th Mar 20179:35 amRNSSch 1 Update - Duke Royalty Limited
17th Mar 20176:17 pmRNSResult of Fundraising
16th Mar 20175:03 pmRNSProposed Placing and Subscription
21st Feb 201711:25 amRNSSch 1 Update - Duke Royalty Limited
1st Feb 201711:00 amRNSSchedule 1 - Duke Royalty Limited
11th Jan 20177:01 amRNSAppointment of Chief Investment Officer
11th Jan 20177:00 amRNSChange of Advisors and Operational Update
17th Nov 20169:00 amRNSUnaudited interim results
1st Sep 201612:02 pmRNSResult of AGM
25th Jul 20167:00 amRNSFinal Results
29th Mar 20161:32 pmRNSSale of investments
7th Mar 20167:00 amRNSBoard Changes and Corporate Update
3rd Feb 20167:00 amRNSDirector/PDMR Shareholding
19th Jan 20169:55 amRNSChange of Adviser
14th Dec 201511:40 amRNSDirector/PDMR Shareholding
23rd Nov 20157:00 amRNSInterim results
29th Oct 20157:00 amRNSHolding(s) in Company
29th Oct 20157:00 amRNSCorrection: Appointment and Issue of Shares
28th Oct 20157:00 amRNSMr Justin Cochrane Appointment and Issue of Shares
12th Oct 20155:16 pmRNSHolding(s) in Company
17th Sep 20153:40 pmRNSFormation of Healthcare Investment Committee
14th Sep 201512:41 pmRNSHolding(s) in Company
11th Sep 20157:00 amRNSDirector share purchase
10th Sep 201512:00 pmRNSResult of AGM
7th Sep 20159:15 amRNSGrant of options
7th Sep 20157:00 amRNSPlacing
7th Sep 20157:00 amRNSCollaboration with Oliver Wyman
4th Aug 201512:21 pmRNSChanges to NAV Reporting
27th Jul 20154:12 pmRNSResults for the year ended 31 March 2015
16th Jun 201511:36 amRNSResult of EGM
10th Jun 201511:21 amRNSHolding(s) in Company
2nd Jun 20151:57 pmRNSHolding(s) in Company
28th May 201511:00 amRNSEGM, proposed changes to board & investing policy
26th May 20159:58 amRNSHolding(s) in Company
26th May 20159:57 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
26th May 20159:56 amRNSHolding(s) in Company
22nd May 20155:15 pmRNSRepayment of zero dividend preference shares
20th May 20157:00 amRNSPlacing
15th May 201511:08 amRNSSale of investment
20th Apr 20155:36 pmRNSNet Asset Value(s)
19th Jan 20154:27 pmRNSNet Asset Value(s)
30th Dec 20143:07 pmRNSInterim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.